CINECA IRIS Institutional Research Information System

FIORAVANTI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.932
EU - Europa 1.183
AS - Asia 1.093
SA - Sud America 139
AF - Africa 54
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 6.408
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.853
SG - Singapore 384
CN - Cina 304
IT - Italia 301
DE - Germania 274
HK - Hong Kong 190
SE - Svezia 170
BR - Brasile 119
GB - Regno Unito 88
BG - Bulgaria 87
VN - Vietnam 72
CA - Canada 63
TR - Turchia 60
AT - Austria 50
FI - Finlandia 48
FR - Francia 41
RU - Federazione Russa 40
IN - India 27
CI - Costa d'Avorio 25
UA - Ucraina 21
JP - Giappone 19
BE - Belgio 18
PL - Polonia 11
NL - Olanda 10
NG - Nigeria 8
EC - Ecuador 7
MX - Messico 7
KR - Corea 6
SN - Senegal 6
AR - Argentina 5
BD - Bangladesh 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
MA - Marocco 5
SA - Arabia Saudita 5
AU - Australia 4
CO - Colombia 4
ID - Indonesia 4
LT - Lituania 4
PK - Pakistan 4
ZA - Sudafrica 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
AL - Albania 2
AZ - Azerbaigian 2
CR - Costa Rica 2
EG - Egitto 2
JO - Giordania 2
LB - Libano 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
A1 - Anonimo 1
AM - Armenia 1
BB - Barbados 1
BJ - Benin 1
BN - Brunei Darussalam 1
CL - Cile 1
ES - Italia 1
EU - Europa 1
GD - Grenada 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IE - Irlanda 1
IL - Israele 1
IQ - Iraq 1
KH - Cambogia 1
MD - Moldavia 1
NP - Nepal 1
PE - Perù 1
SO - Somalia 1
SY - Repubblica araba siriana 1
Totale 6.408
Salva come PNG Salva come JPEG
Città #
Woodbridge 425
Ann Arbor 408
Fairfield 384
Ashburn 382
Houston 321
Chandler 222
Singapore 204
Hong Kong 189
Dallas 182
Seattle 182
Santa Clara 178
Wilmington 170
Cambridge 138
Serra 132
Sofia 87
Shanghai 79
Beijing 74
New York 65
Ottawa 48
Boardman 45
Vienna 45
Dong Ket 39
Los Angeles 39
Des Moines 36
Izmir 36
Princeton 36
Medford 35
Lawrence 34
Dearborn 26
Falls Church 26
Abidjan 25
Columbus 23
The Dalles 23
Frankfurt am Main 22
Munich 21
London 20
Rho 19
Boulder 18
Brussels 18
Istanbul 18
Nanjing 18
Jacksonville 17
San Jose 17
Buffalo 16
San Diego 16
Tokyo 16
Council Bluffs 15
Florence 15
Nürnberg 15
Redondo Beach 14
Milan 13
São Paulo 13
Turku 13
Bremen 12
Fuzhou 12
Nanchang 11
Pune 11
Seacroft 11
Düsseldorf 9
Pisa 9
Shenyang 9
Ho Chi Minh City 8
Lagos 8
Ogden 8
Redwood City 8
Marseille 7
Dakar 6
Hanoi 6
Lancaster 6
Montreal 6
San Francisco 6
Seoul 6
Changsha 5
Kunming 5
Norwalk 5
Phoenix 5
Warsaw 5
Atlanta 4
Boston 4
Indiana 4
Quito 4
Stockholm 4
Toronto 4
Wroclaw 4
Auburn Hills 3
Bexley 3
Copenhagen 3
Da Nang 3
Denver 3
Groningen 3
Hefei 3
Jiaxing 3
Lauterbourg 3
Poplar 3
Porto Alegre 3
Quanzhou 3
Rio de Janeiro 3
Tianjin 3
Washington 3
Amman 2
Totale 4.931
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 383
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 278
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 245
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 239
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 233
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 228
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 224
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 222
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 219
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 208
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 204
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 191
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 191
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 189
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 184
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 183
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine 182
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 160
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 157
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 155
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 153
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer 151
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 145
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 144
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 139
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 137
Derivati a nucleo pirazolo[3,4-d]pirimidinico quali inibitori di proteine tirosina chinasi 136
The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells 135
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 132
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 131
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. 114
null 101
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 96
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 96
null 89
Totale 6.503
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021254 0 0 0 0 0 22 7 48 36 51 26 64
2021/2022473 10 41 20 14 76 65 16 21 25 26 22 137
2022/2023652 85 99 60 74 66 89 3 37 105 2 29 3
2023/2024244 21 18 27 5 26 64 9 20 5 6 14 29
2024/20251.173 3 44 5 90 138 142 65 50 150 147 110 229
2025/2026800 105 127 211 111 147 99 0 0 0 0 0 0
Totale 6.503